Ivan Foeldvari
Overview
Explore the profile of Ivan Foeldvari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
3210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Weiss P, Brandon T, Aggarwal A, Burgos-Vargas R, Colbert R, Horneff G, et al.
Arthritis Rheumatol
. 2024 Jul;
76(12):1797-1808.
PMID: 39039899
Objective: The goal was to develop and validate classification criteria for axial juvenile spondyloarthritis (SpA; AxJSpA). Methods: This international initiative consisted of four phases: (1) item generation, (2) item reduction,...
12.
Brunner H, Schulert G, Sproles A, Thornton S, Cornejo G, Anton J, et al.
Arthritis Res Ther
. 2024 Jun;
26(1):125.
PMID: 38918871
Background: Juvenile idiopathic arthritis (JIA) comprises a heterogeneous group of conditions that can cause marked disability and diminished quality of life. Data on predictors of clinical response are insufficient to...
13.
Desai Y, Jaki T, Beresford M, Burnett T, Eleftheriou D, Jacobe H, et al.
AMRC Open Res
. 2024 May;
3:20.
PMID: 38708070
Background: Evidence is lacking for safe and effective treatments for juvenile localised scleroderma (JLS). Methotrexate (MTX) is commonly used first line and mycophenolate mofetil (MMF) second line, despite a limited...
14.
Milatz F, Klotsche J, Niewerth M, Sengler C, Windschall D, Kallinich T, et al.
Arthritis Res Ther
. 2024 Apr;
26(1):82.
PMID: 38600543
Background: Previous studies have shown that growing up with rheumatic conditions can fuel dissatisfaction and psychological distress, which in turn affects disease self-management and treatment adherence. Primary objective of this...
15.
Foeldvari I, Bohn M, Petrushkin H, Angeles Han S, Bangsgaard R, Calzada-Hernandez J, et al.
Br J Ophthalmol
. 2024 Apr;
109(3):372-376.
PMID: 38575198
Background: Juvenile idiopathic arthritis (JIA)-associated uveitis typically presents as a silent chronic anterior uveitis and can lead to blindness. Adherence to current screening guidelines is hampered by complex protocols which...
16.
Milatz F, Hansmann S, Klotsche J, Niewerth M, Kallinich T, Dressler F, et al.
Pediatr Rheumatol Online J
. 2024 Mar;
22(1):39.
PMID: 38509613
Background: Physical active lifestyles are essential throughout growth and maturation and may offer potential preventive and therapeutic benefit in patients with juvenile idiopathic arthritis (JIA). Insufficient physical activity (PA), in...
17.
Knobler R, Geroldinger-Simic M, Kreuter A, Hunzelmann N, Moinzadeh P, Rongioletti F, et al.
J Eur Acad Dermatol Venereol
. 2024 Mar;
38(7):1281-1299.
PMID: 38456518
The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to...
18.
Kuemmerle-Deschner J, Kallinich T, Henes J, Kortus-Gotze B, Oommen P, Rech J, et al.
RMD Open
. 2024 Feb;
10(1).
PMID: 38360038
Objective: Interim analysis of the RELIANCE registry, an on-going, non-interventional, open-label, multicentre, prospective study evaluating the long-term safety, dosing regimens and effectiveness of canakinumab in patients with cryopyrin-associated periodic syndromes...
19.
Hoffmann-Vold A, Maher T, Philpot E, Ashrafzadeh A, Barake R, Barsotti S, et al.
Lancet Rheumatol
. 2024 Jan;
2(2):e71-e83.
PMID: 38263663
Background: Systemic sclerosis-associated interstitial lung disease (ILD) carries a high mortality risk; expert guidance is required to aid early recognition and treatment. We aimed to develop the first expert consensus...
20.
Lovell D, Tzaribachev N, Henrickson M, Simonini G, Griffin T, Alexeeva E, et al.
Rheumatology (Oxford)
. 2024 Jan;
63(SI2):SI195-SI206.
PMID: 38243722
Objective: The aim of this study was to report the interim 5-year safety and effectiveness of abatacept in patients with JIA in the PRINTO/PRCSG registry. Methods: The Abatacept JIA Registry...